SH2D1A and MET

Data Source:
BioGRID (pull down)

		SH2D1A	MET
Description		SH2 domain containing 1A	MET proto-oncogene, receptor tyrosine kinase
Image
GO Annotations	Cellular Component	Cytoplasm Cytosol	Extracellular Region Plasma Membrane Integral Component Of Plasma Membrane Basal Plasma Membrane Cell Surface Integral Component Of Membrane Receptor Complex
	Molecular Function	Protein Binding	Protein Tyrosine Kinase Activity Transmembrane Receptor Protein Tyrosine Kinase Activity Hepatocyte Growth Factor-activated Receptor Activity Protein Binding ATP Binding Semaphorin Receptor Activity Protein Phosphatase Binding Identical Protein Binding
	Biological Process	Adaptive Immune Response Humoral Immune Response Cellular Defense Response Cell-cell Signaling Innate Immune Response Positive Regulation Of Natural Killer Cell Mediated Cytotoxicity Regulation Of Immune Response Negative Regulation Of T Cell Receptor Signaling Pathway	MAPK Cascade Endothelial Cell Morphogenesis Liver Development Phagocytosis Signal Transduction Cell Surface Receptor Signaling Pathway Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Multicellular Organism Development Nervous System Development Negative Regulation Of Autophagy Cell Migration Peptidyl-tyrosine Phosphorylation Neuron Differentiation Pancreas Development Positive Regulation Of Microtubule Polymerization Positive Regulation Of Kinase Activity Negative Regulation Of Rho Protein Signal Transduction Entry Of Bacterium Into Host Cell Positive Regulation Of Transcription By RNA Polymerase II Hepatocyte Growth Factor Receptor Signaling Pathway Branching Morphogenesis Of An Epithelial Tube Positive Chemotaxis Negative Regulation Of Stress Fiber Assembly Positive Regulation Of Protein Kinase B Signaling Establishment Of Skin Barrier Negative Regulation Of Thrombin-activated Receptor Signaling Pathway Semaphorin-plexin Signaling Pathway Negative Regulation Of Hydrogen Peroxide-mediated Programmed Cell Death Negative Regulation Of Guanyl-nucleotide Exchange Factor Activity Positive Regulation Of Endothelial Cell Chemotaxis
Pathways		Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels
Drugs			K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Fostamatinib Tivantinib Brigatinib Amuvatinib
Diseases		Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)	Renal cell carcinoma Cholangiocarcinoma Gastric cancer
GWAS			Blood protein levels ( 30072576) Gamma glutamyl transferase levels ( 29403010) HDL cholesterol levels ( 28334899) Hematocrit ( 28017375) Lung function (FEV1/FVC) ( 30804560) Medication use (beta blocking agents) ( 31015401) Multiple sclerosis (severity) ( 19010793) PR segment ( 24850809) Pulse pressure ( 30578418) Resting heart rate ( 29769521 27798624) Triglyceride levels ( 28334899) Triglycerides ( 24097068) Waist-to-hip ratio adjusted for BMI ( 26426971) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971)
Interacting Genes		32 interacting genes: AR ARHGEF6 ARHGEF7 ATF3 CCDC74A CD84 DOK1 EGFR ERBB2 ERBB3 ERBB4 FYB1 FYN GRB2 KIT LCK LETMD1 LHX3 LHX4 LY9 MAPK11 MAPK14 MET NCK1 NGEF OLIG1 PTK2 SLAMF1 SLAMF6 SLAMF7 TNK2 ZNHIT1	112 interacting genes: ABL2 BAG1 BCAR3 BLK BTK CASP3 CBL CCND2 CD44 CDK4 CDK6 CDKN2B CNR1 CRK CTNNB1 CTTN DAPK3 DCN DNAJA3 EGFR EPHA2 ERBB2 FAS FES FGFR4 FGR FZR1 GAB1 GLIS2 GLMN GRB14 GRB2 GRB7 HCK HGF HGS HSH2D INPP5D INPPL1 ITGB1 ITGB4 ITK KDELR2 LATS2 LCK LYN MAP2K3 MAP2K5 MATK MUC20 MYC NCK1 NCK2 NF2 PCBD2 PIK3R1 PIK3R2 PIK3R3 PLCG1 PLCG2 PLXNB1 PTK6 PTPN11 PTPRB PTPRJ RAF1 RANBP10 RANBP9 RASA1 RASSF1 SH2B1 SH2B2 SH2B3 SH2D1A SH2D1B SH2D2A SH2D3C SH3BP2 SHB SHC1 SHC2 SHC3 SHC4 SHD SLA2 SMC1A SNAPIN SNX2 SOCS1 SOCS2 SOCS3 SOCS5 SOCS6 SPSB1 SRC STAP1 STAT3 STK11 SYK TEC TERT TNS1 TNS2 TNS3 TNS4 TP53 TXK VAV1 VAV2 VAV3 YES1 ZAP70
Entrez ID		4068	4233
HPRD ID		02390	01280
Ensembl ID		ENSG00000183918	ENSG00000105976
Uniprot IDs		O60880	A0A024R728 A0A024R759 B4DLF5 E6Y365 P08581
PDB IDs		1D1Z 1D4T 1D4W 1KA6 1KA7 1M27	1FYR 1R0P 1R1W 1SHY 1SSL 1UX3 2G15 2RFN 2RFS 2UZX 2UZY 2WD1 2WGJ 2WKM 3A4P 3BUX 3C1X 3CCN 3CD8 3CE3 3CTH 3CTJ 3DKC 3DKF 3DKG 3EFJ 3EFK 3F66 3F82 3I5N 3L8V 3LQ8 3Q6U 3Q6W 3QTI 3R7O 3RHK 3U6H 3U6I 3VW8 3ZBX 3ZC5 3ZCL 3ZXZ 3ZZE 4AOI 4AP7 4DEG 4DEH 4DEI 4EEV 4GG5 4GG7 4IWD 4K3J 4KNB 4MXC 4O3T 4O3U 4R1V 4R1Y 4XMO 4XYF 5DG5 5EOB 5EYC 5EYD 5HLW 5HNI 5HO6 5HOA 5HOR 5HTI 5LSP 5T3Q 5UAB 5UAD 5YA5 6GCU 6I04 6SD9 6SDC 6SDD 6SDE 6UBW
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?